Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Biosion Out-Licenses Siglec-15 mAb for Solid Tumors in $226 Million Pact

publication date: Mar 29, 2022

Nanjing Biosion out-licensed global rights (ex-China) to Pyxis Oncology for an immunotherapy aimed at solid tumor cancers in a $226 million agreement. BSI-060T, now known as PYX-106, is Biosion's anti-Siglec-15 mAb. The company will receive a $10 million up-front license fee, $216 million in milestones and royalties on commercial sales. Pyxis, which also has an opportunity to in-license other Biosion anti-Siglec-15 candidates, plans to submit an IND for PYX-106 in the US during Q2 of this year. More details....

Stock Symbols: (NSDQ: PYXS)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China